4-(3-甲基丁基)嘧啶 | 116186-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(3-甲基丁基)嘧啶
• 英文名称: 4-(3-methylbutyl)pyrimidine
• CAS: 116186-27-7
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: UQYXNNGIYNFZFW-UHFFFAOYSA-N

物化性质

• 沸点：
  222.0±9.0 °C(Predicted)
• 密度：
  0.947±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-甲基丁基)嘧啶 以 丙酮 为溶剂， 反应 4.25h， 生成 4-甲基嘧啶
  参考文献：
  名称：

  Photochemical hydrogen abstraction by singlet and triplet n.pi.* states of aromatic nitrogen: fragmentation of 4-alkylpyrimidines and 2-alkylquinolines

  摘要：

  DOI：

  10.1021/ja00166a033
• 作为产物：
  描述：

  1-chloro-6-methyl-hept-1-en-3-one 、 formamide 反应 6.0h， 以20%的产率得到4-(3-甲基丁基)嘧啶
  参考文献：
  名称：

  两个三联体介导 4-酰基-6-烷基嘧啶中氮对氢的分子内光化学提取

  摘要：

  反应和获得​​甲基-4乙酰-6嘧啶和d'羟基-1'环丙基-4甲基-6嘧啶

  DOI：

  10.1021/ja00228a030

文献信息

• Fused Heterocyclic Compounds as Ion Channel Modulators
  申请人：Kobayashi Tetsuya

  公开号：US20120010192A1

  公开（公告）日：2012-01-12

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类是钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该类化合物的结构由式I给出：其中R1、R2、R3、R4和R5如本文所述，以及制备和使用该类化合物的方法，以及含有这些化合物的药物组合物。
• Two triplets mediating intramolecular photochemical abstraction of hydrogen by nitrogen in 4-acyl-6-alkylpyrimidines
  作者：Martha A. Brumfield、William C. Agosta

  DOI：10.1021/ja00228a030

  日期：1988.9

  Mecanisme de la reaction et obtention de methyl-4 acetyl-6 pyrimidine et d'hydroxy-1' cyclopropyl-4 methyl-6 pyrimidine

  反应和获得​​甲基-4乙酰-6嘧啶和d'羟基-1'环丙基-4甲基-6嘧啶
• OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF
  申请人：Mikamiyama Hidenori

  公开号：US20110098276A1

  公开（公告）日：2011-04-28

  The invention relates to oxycarbamoyl compounds of Formula I: The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式I的氧化氨基甲酰化合物：本发明还涉及使用式I的化合物来治疗、预防或改善对钙通道阻滞有反应的疾病，尤其是N型钙通道。本发明的化合物特别适用于治疗疼痛。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150080370A1

  公开（公告）日：2015-03-19

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是钠通道抑制剂，用于治疗各种疾病状态，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由公式I给出：其中R1，R2，R3，R4和R5如本文所述，涉及该化合物的制备和使用方法以及包含该化合物的制药组合物。
• HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF
  申请人：Xalud Therapeutics, Inc.

  公开号：US20210087202A1

  公开（公告）日：2021-03-25

  The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.